| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/100-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | LIM domain kinase 2 |
| Entrez GeneID | 3985 |
| WB Predicted band size | Calculated MW: 72 kDa; Observed MW: 72 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | Synthetic peptide of human LIMK2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是关于LIM Kinase 2(LIMK2)抗体的3篇代表性文献的简要总结：
---
1. **文献名称**: "LIM kinase 2 modulates actin dynamics and promotes tumor progression in breast cancer"
**作者**: Davila M, et al.
**摘要**: 本研究利用特异性LIMK2抗体检测了乳腺癌细胞中LIMK2的表达水平，发现其通过磷酸化cofilin调控细胞骨架重组，促进肿瘤细胞的迁移和侵袭。研究还表明LIMK2高表达与患者预后不良相关。
---
2. **文献名称**: "Role of LIMK2 in amyloid-beta-induced neurotoxicity and synaptic dysfunction"
**作者**: Hernandez F, et al.
**摘要**: 通过免疫印迹和免疫荧光实验(使用LIMK2特异性抗体)，作者发现阿尔茨海默病模型中，LIMK2活性升高导致tau蛋白异常磷酸化和神经元突触损伤，提示其作为神经退行性疾病的潜在治疗靶点。
---
3. **文献名称**: "Development and validation of a high-specificity LIMK2 monoclonal antibody for functional studies"
**作者**: Wang Y, et al.
**摘要**: 本文报道了一种新型抗LIMK2单克隆抗体的开发，通过表位映射和交叉反应性验证其特异性，并成功应用于流式细胞术和免疫组化，为研究LIMK2在细胞迁移和癌症中的功能提供了可靠工具。
---
4. **文献名称**: "LIMK2 regulates prostate cancer progression via the STAT3 signaling pathway"
**作者**: Li X, et al.
**摘要**: 使用LIMK2抗体进行组织芯片分析，发现前列腺癌中LIMK2过表达与STAT3信号激活相关，并通过促进上皮-间质转化(EMT)增强转移能力，提示其作为癌症治疗的分子靶点。
---
以上文献均聚焦于LIMK2的生物学功能及其抗体的应用，涵盖肿瘤学、神经科学及抗体开发领域。
LIM kinase 2 (LIMK2) is a serine/threonine kinase belonging to the LIM kinase family, which plays a critical role in regulating cytoskeletal dynamics by phosphorylating and inactivating cofilin, an actin-depolymerizing protein. This activity modulates actin filament reorganization, influencing processes such as cell migration, division, and synaptic plasticity. LIMK2 is structurally characterized by two N-terminal LIM domains, which mediate protein-protein interactions, and a C-terminal kinase domain. It is activated by upstream Rho GTPase signaling pathways, particularly through ROCK and PAK kinases, linking extracellular signals to cytoskeletal remodeling.
LIMK2 antibodies are essential tools for studying its expression, localization, and function in both physiological and pathological contexts. Dysregulation of LIMK2 has been implicated in various diseases, including cancer metastasis, neurological disorders (e.g., Alzheimer’s disease), and cardiovascular conditions. For example, elevated LIMK2 levels in tumors correlate with enhanced invasiveness, making it a potential therapeutic target. Researchers use LIMK2 antibodies in techniques like Western blotting, immunohistochemistry, and immunofluorescence to explore its role in cell signaling pathways, drug response, and disease mechanisms. These antibodies also aid in evaluating LIMK2 inhibition strategies in preclinical studies. Specificity and validation (e.g., knockout controls) are crucial to ensure accurate detection, given structural similarities with LIMK1. Understanding LIMK2's multifaceted roles continues to advance insights into cytoskeletal regulation and disease pathogenesis.
×
